Me

#REV Understand why the little weakness was few days ago then back higher Cash balance increasing on top of the £2m balance as the SharePrice is building strength it great 👌 investegate.co.uk/announceme…

I'm increasingly excited about Avacta #AVCT because I genuinely believe the next eight to twelve weeks could be transformational. As everyone knows, they've developed a technology that allows incredibly powerful drugs to be delivered much more precisely to 1/23

#AVCT AVA6103 began end of March. On 16 September AVCT announced “clinical proof of mechanism for the preCISION platform.” We now know the reason the CEO was happy to state that: they already sat on biopsy data which confirmed the tumour reservoir model in human. The CEO went on to say (last week, interims) this is the most remarkable alignment of pre-clinical and clinical data she has seen in over two decades. So, we know: They sit on biopsies. They flew through C1,2,3,4. The safety profile is phenomenal. They are sustaining the release of Exatecan (for days) in human. They sit on confirmed platform technology. Given they have “a few” biopsies “in their back pocket”, these are likely coming from both mandatory backfill and not mandatory consent. Bingo is demonstration they have established a dose:response relationship as the cohorts have escalated and this translates into signs of effigy (which then increase as the dose escalates). Do they already have that? Well, they had a stage 4 pancreatic cancer patient still on drug in September (March dosing), they went after pancreatic again in C2, again in C3, then headed to AACR pancreatic. All of the C3 patients remained on drug at the beginning of September. The (modern, best practice) criteria to backfill in BOIN is efficacy. See MD Anderson’s public criteria. As ever, Coughlin only tells you she suspects she’s going to ace the test when she already knows the answers. All eyes now on how fast they move through Cohort 5. Cohort 5 is scheduled to be equivalent to the absolute dose of Enhertu so the speed of it will be the perfect test of preCISION’s specificity. Jet plane.

This is the #AVCT slide showing upcoming news flow. A very busy end-of-year schedule is planned. I found it very interesting that the AVA6103 Ph. 1 efficacy time bar sits mainly in Q1. Early 2027, I believe, was the wording used. We get started in c. 1 week when ESMO kicks off.

#GCM Breaking out into close. Huge meeting tomorrow in Bangladesh.

BBN, I really don’t think it’s about Avacta taking too little cash in the raise. Rather, I’m 95% sure it’s about overly leveraged #AVCT longs - prior to this week - thinking it’d never drop to 66/67 ever again, and being margin called today. Hopefully that’s the margin calls wiped out and we see a big bounce tomorrow. 6103 news from a few weeks ago was genuinely transformational for the company, and we’re now trading >10p below the level at which said news was released. Madness. I didn’t take part in the placing but I will be adding down here!

#GCM £££'s